Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3563729 | 0.98 | MAOB (0.55) | GFERMAOBSIGMAR1KCNH2HRH3 | |
| SCHEMBL8076000 | 0.94 | SIGMAR1 (0.62) | GFERMAOBSIGMAR1KCNH2HRH3 | |
| SCHEMBL15807549 | 0.92 | SIGMAR1 (0.66) | GFERMAOBSIGMAR1KCNH2HRH3 | |
| SCHEMBL11384024 | 0.89 | CYP3A4 (0.48) | GFERMAOBSIGMAR1KCNH2HRH3 | |
| SCHEMBL9670561 | 0.89 | SIGMAR1 (0.64) | SIGMAR1KCNH2HRH3AOC3TAAR1 | |
| SCHEMBL189454 | 0.86 | HRH3 (0.67) | GFERMAOBSIGMAR1HRH3AOC3 | |
| Hydrochloric Acid SCHEMBL6675945 | 0.84 | HRH3 (0.64) | GFERMAOBSIGMAR1HRH3AOC3 | |
| SCHEMBL5708331 | 0.84 | HRH3 (0.64) | GFERMAOBSIGMAR1HRH3AOC3 | |
| SCHEMBL13897016 | 0.83 | SIGMAR1 (0.58) | GFERMAOBSIGMAR1KCNH2AOC3 | |
| SCHEMBL9671700 | 0.82 | HRH3 (0.74) | SIGMAR1KCNH2HRH3AOC3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391730-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2023-12-07 | — | — | US | disclosed |
| WO-2022076735-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-04-14 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20190084943-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-20170327472-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327472-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| EP-1551810-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | Aventis Pharma Deutschland GmbH (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| WO-2004012648-A2 | SUBSTITUTED DIARYL HETEROCYCLES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004011438-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-05 | — | — | WO | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
| CN-1319090-A | Novel substuted indolimones, their preparation process and use as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-10-24 | — | — | CN | disclosed |
| EP-1115704-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018734-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | GPR119, GLP1R, SLC5A2 | GFER 3796/4885MAOB 12/4885SIGMAR1 2577/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | GFER 3828/4885MAOB 1296/4885SIGMAR1 4550/4885 |
| US-20170327472-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | GFER 3591/4885MAOB 2687/4885SIGMAR1 864/4885 |
| US-20230391730-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | BPTF, BRPF3, PHF6 | GFER 3314/4885MAOB 4660/4885SIGMAR1 1291/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | GFER 3792/4885MAOB 1142/4885SIGMAR1 4627/4885 |
| US-20190084943-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | GFER 3591/4885MAOB 2687/4885SIGMAR1 864/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | GFER 3792/4885MAOB 1142/4885SIGMAR1 4627/4885 |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | GFER 4028/4885MAOB 1322/4885SIGMAR1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.